#None #Pain Management #Grünenthal #DHSH

Grünenthal and DKSH Partner to Expand Pain Relief Access

Grünenthal, a global leader in pain management and medical research, has partnered with DKSH, a well-known provider of Market Expansion Services. This collaboration is aimed at introducing four vital pain medications: Qutenza®, Vimovo®, Palexia®, and Zomig® to eight key markets in the Asia-Pacific region. The countries included in this initiative are Hong Kong, Indonesia, Malaysia, Philippines, Singapore, Taiwan, Thailand, and Vietnam.

Significance of the Partnership

Pain management remains a critical healthcare issue within Asia-Pacific, exacerbated by an aging population and a high prevalence of chronic diseases. This partnership is an essential part of Grünenthal's strategy to enhance patient care and widen access to innovative treatments.

Jan Adams, Chief Commercial Officer of Grünenthal, emphasized the importance of this alliance, stating, "Our partnership with DKSH enables us to take a significant step towards expanding access to effective therapies, targeting the millions of individuals affected by pain across the region."

Roles of Grünenthal and DKSH

Under the agreement, DKSH takes the lead in commercializing these medicines in the targeted regions. This includes seeking local marketing authorizations as well as handling all marketing, medical, market access, sales, and distribution activities. Conversely, Grünenthal maintains its responsibility for the manufacturing of these medications, utilizing its cutting-edge global manufacturing facilities.

This partnership marks an extension of their collaboration that initially began in 2023, with DKSH already managing other Grünenthal medications such as Nebido® and Tramal® in selected markets.

Overview of the Medications

1. Qutenza® - A topical treatment containing an 8% capsaicin formulation, primarily indicated for peripheral neuropathic pain in adults, can also be used in conjunction with other pain medications.

2. Vimovo® - This combination of esomeprazole and naproxen offers symptomatic relief for ailments like osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis while helping patients susceptible to NSAID-related gastric issues.

3. Palexia® - This powerful analgesic is utilized for managing severe chronic pain requiring opioid treatment in adults and children over six, available in prolonged-release and immediate-release formats.

4. Zomig® - Effective for treating acute migraine headaches in adults and adolescents, Zomig is available in tablet and nasal spray forms.

The Challenge of Pain in Asia-Pacific

Chronic pain spans across various demographics in Asia-Pacific, which is concerning. Public health records suggest that hundreds of millions may be living with chronic pain conditions. According to experts, addressing this situation requires innovative care solutions to meet the diverse needs of patients.

Patrik Grande, Global Head of DKSH's Healthcare Business Unit, stated, "We are excited to expand our partnership with Grünenthal into more markets. Leveraging our comprehensive market solutions, we aim to improve access to innovative therapies for many patients across the Asia-Pacific region."

Conclusion

The collaboration between Grünenthal and DKSH represents a crucial development in pain management within the Asia-Pacific area. As these new medications reach local markets, they hold the potential to significantly alter the landscape of pain treatment, improving the quality of life for countless patients persevering through chronic pain disorders.

With a mission to ensure that effective pain management solutions are accessible, Grünenthal and DKSH are setting a precedent for future healthcare collaborations. For additional information about these medications and their availability, visit Grünenthal's official website.